Google
BLCO 株価分析 — BAUSCH + LOMB CORP (Healthcare >> Medical Instruments & Supplies)
BLCO に関するよくある質問
BLCOのPER（株価収益率）は？
BAUSCH + LOMB CORP（BLCO）は現在PER -104.62倍で取引されています。
BLCOのROE（自己資本利益率）は？
BAUSCH + LOMB CORPのROEは-2.68%です。
BLCOの配当利回りは？
BAUSCH + LOMB CORPの配当利回りは0.00%です。
BLCOの品質スコア（Quality Score）は？
当社のAIはBLCOの総合財務品質を100点中38点と評価しています。収益性・成長性・負債・利益の安定性に基づく評価です。
BLCOは今が買い時ですか？
当社AIのタイミングスコアは100点中89点で、テクニカル指標とモメンタムから見た現在価格の相対的な魅力度を示します。
BLCOはどのセクターに属しますか？
BAUSCH + LOMB CORPはHealthcare >> Medical Instruments & Suppliesセクターに分類されます（NYSE市場）
BLCO AI Analysis Summary
Our AI summary for BLCO: BAUSCH + LOMB CORP (NYSE), Healthcare >> Medical Instruments & Supplies sector. The stock currently trades at a P/E of -104.62, ROE of -2.68%, a dividend yield of 0.00%. Its financial Quality Score stands at 38/100 — fundamentals below the market average. The AI Timing Score is 89/100 — multiple technical signals currently support price momentum. All scores are recomputed automatically after each market close from official exchange data. This is systematically generated analysis, not personalized investment advice.
|
USD 16.91
Price
-0.08
(-0.47%)
Day Change
|
|
|---|
BLCO, ファンダメンタルスコアはnot good ( ファンダメンタル = 38) but テクニカルスコアは ...(Sign In to See)...
Loading chart...
- Signal
- UNDERPERFORM
- Signal Description
- Company financial health is Not Good
- Reason
-
ROEが低い
ROAが低い
ROEの伸びが低い
平均ROEが低い
ROAの伸びが低い
NPMが低い
NPMの伸びが低い
NPMの伸びが低い
88 Sign in
TIMING
- Signal
- OUTPERFORM
- Signal Descri...
- Good
- Reason
- Momentum indicators aligned on the daily timeframe
In details, quality factors are not good , financial health is not good , and ability to make profit is not quite good , ...
| Deepscope 分析 |
|
45% |
| In Recommendations? | Not in any sections |
| Select Rate | 0.00 From 30 days period |
| Watch Rate | 0.00 From 30 days period |
| News Score | 99 |
| Magic Formula Rank by ROA |
N/A
|
| Magic Formula Rank by ROE |
N/A
|
| Magic Formula Rank by ROIC |
N/A
|
| Price | 16.91 |
| PBV / Sector |
0.94 / 3.37
GREAT
|
| Earning Per Share | -0.48 |
| PE / Sector |
N/A / 44.25
|
| PEG or PE/Growth / Sector |
0.07 / -1.35
GREAT
|
| Average 1M Daily Value |
6.52 M
|
| Average 1W Daily Value |
9.38 M
|
| Timing Factors |
|
71% |
| Financial Health |
|
45% |
| ポイントになる統計 |
|
56% |
| 配当 |
|
4% |
| 登録情報 |
| Analyze Date | 2026-08-01 07:59:33 |
| Symbol | BLCO |
| Name | BAUSCH + LOMB CORP |
| Sector | Healthcare >> Medical Instruments & Supplies |
| Market | NYSE |
| Listed Shares | 357.17 M |
| Par Value | N/A |
| Calculated From | Quarter |
| Sign | N/A |
| Market Cap (M.USD) / Sector Average | 6,068.24 / 16,159.14 |
| ニュース |
| Estimation Consensus | See at WSJ.com |
| Full details | See at WSJ.com |
| Chart | See in Chart feature |
| News | See at Yahoo Finance |
Address: 520 Applewood Crescent, Vaughan, ON, Canada, L4K 4B4
Phone: 905 695 7700
Website: https://www.bausch.com
Employees: 13,000
Description: Bausch + Lomb Corporation operates as an eye health company in the United States, Puerto Rico, China, France, Japan, Germany, the United Kingdom, Canada, Russia, Spain, Italy, Mexico, Poland, and internationally. It operates in three segments: Vision Care, Pharmaceuticals, and Surgical. The Vision Care segment provides contact lens that covers the spectrum of wearing modalities, including daily disposable and frequently replaced contact lenses; and contact lenses that are indicated for therapeutic use and provide optical correction during healing. It also offers contact lens care products, eye vitamins, mineral supplements, and over-the-counter eye drops that address various conditions, such as eye allergies, conjunctivitis, dry eye, and redness relief. The Pharmaceuticals segment offers proprietary and generic pharmaceutical products for post-operative treatments, as well as for the treatment of glaucoma, eye inflammation, ocular hypertension, dry eyes, and retinal diseases. The Surgical segment provides medical device equipment, consumables, and technologies for the treatment of cataracts, corneal, vitreous, and retinal eye conditions; and intraocular lenses and delivery systems, phacoemulsification equipment, and other surgical instruments and devices for cataract surgery. The company sells its products and services through direct sales forces and independent distributors. Bausch + Lomb Corporation was founded in 1853 and is headquartered in Vaughan, Canada. Bausch + Lomb Corporation operates as a subsidiary of Bausch Health Companies Inc.
Analyst Ratings & Target Price
ME vs SECTOR Healthcare >> Medical Instruments & Supplies
Click a bubble to view stock details · Bubble size represents market capitalization share
